Journal article · 2026 · Open access

Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies

Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Shatavisa Mukherjee, Shashank Joshi

World Journal of Hepatology, 18(6) · Published 27 June 2026 · DOI 10.4254/wjh.118548

Open full textCite this paper

In brief

“Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies” is a 2026 journal article by Sanjay Bandyopadhyay and 3 co-authors, published in World Journal of Hepatology. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at World Journal of Hepatology.

Citations
0
References
56
Authors
4

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, spanning a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. In addition to liver-related morbidity, MASLD is closely associated with systemic metabolic dysfunction and increased cardiovascular risk, emphasizing the need for mechanism-based therapies. Bile acids are now recognized as key metabolic and immunological signaling molecules acting through receptors such as the farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor Takeda G-protein-coupled receptor 5. This narrative review summarizes current evidence on bile acid receptor signaling in MASLD, focusing on receptor biology, molecular mechanisms, and emerging therapeutic strategies. We discuss how changes in bile acid composition, receptor responsiveness, and downstream signaling contribute to metabolic dysregulation, inflammation, and fibrogenesis, while acknowledging inter-individual heterogeneity and limited stage-specific human data. Particular attention is given to FXR and Takeda G-protein-coupled receptor 5 signaling, their interaction with metabolic and inflammatory pathways, and modulation by gut microbiota-derived bile acid transformations. We also review clinical and translational data on bile acid-targeted therapies, including FXR agonists and norursodeoxycholic acid, highlighting therapeutic promise alongside challenges related to lipid effects, long-term safety, and variable efficacy. Overall, bile acid signaling represents a promising yet complex therapeutic axis in MASLD.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bandyopadhyay, S., Samajdar, S. S., Mukherjee, S., & Joshi, S. (2026). Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies. World Journal of Hepatology, 18(6). https://doi.org/10.4254/wjh.118548

MLA 9

Bandyopadhyay, Sanjay, et al. “Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies.” World Journal of Hepatology, vol. 18, no. 6, 2026. https://doi.org/10.4254/wjh.118548.

Chicago

Bandyopadhyay, Sanjay, Shambo Samrat Samajdar, Shatavisa Mukherjee, and Shashank Joshi. 2026. “Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies.” World Journal of Hepatology 18 (6). https://doi.org/10.4254/wjh.118548.

Harvard

Bandyopadhyay, S. et al. (2026) ‘Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies’, World Journal of Hepatology, 18(6). doi:10.4254/wjh.118548.

IEEE

S. Bandyopadhyay, S. S. Samajdar, S. Mukherjee, and S. Joshi, “Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies,” World Journal of Hepatology, vol. 18, no. 6, 2026, doi: 10.4254/wjh.118548.

BibTeX

@article{bandyopadhyay2026bile,
  title     = {{Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies}},
  author    = {Bandyopadhyay, Sanjay and Samajdar, Shambo Samrat and Mukherjee, Shatavisa and Joshi, Shashank},
  journal   = {World Journal of Hepatology},
  year      = {2026},
  volume    = {18},
  number    = {6},
  doi       = {10.4254/wjh.118548},
  url       = {https://doi.org/10.4254/wjh.118548}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment

  • non-alcoholic fatty liver disease
  • farnesoid X receptor
  • TGR5
  • bile acid signaling
  • nonalcoholic steatohepatitis
  • liver fibrosis
  • FXR agonists
  • inflammation

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Bandyopadhyay, S., Samajdar, S. S., Mukherjee, S., & Joshi, S. (2026). Bile acid receptor signaling in metabolic dysfunction-associated steatotic liver disease: Mechanistic insights and emerging therapeutic strategies. World Journal of Hepatology, 18(6). https://doi.org/10.4254/wjh.118548

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at World Journal of Hepatology: sign in and open the full text from this page.

Who wrote this paper?

Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Shatavisa Mukherjee, Shashank Joshi.

What is the DOI of this paper?

10.4254/wjh.118548, permanently at https://doi.org/10.4254/wjh.118548. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.